Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...

Background: Mood disorders are very common among adolescents and include mainly bipolar disorder (BD) and major depressive disorder (MDD), with overlapping depressive symptoms that pose a significant ...

Background Major depressive disorder is estimated by the WHO to affect more than 300 million people globally, making depression the leading cause of disability worldwide. Antidepressants are commonly ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

(A ketamine-derived drug called esketamine is approved for some people as part of treatment-resistant major depressive disorder ... usually get the esketamine nasal spray twice a week for one ...

Major depressive disorder (MDD), also referred to as clinical depression or depression, is a mood disorder where a person has a consistently low or depressed mood and no longer finds interest in ...

Opens in a new tab or window A study suggested that a shortage of immediate-release mixed amphetamine salts (Adderall) to treat attention deficit-hyperactivity disorder (ADHD) may have prompted a ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

Spravato was first approved for use in 2019 to treat people with major depressive disorder who did not respond to at least two other antidepressants. Under that approval, patients had to take an oral ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...